Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
22 août 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
15 août 2023 03h01 HE
|
Mainz BioMed NV
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023 BERKELEY, Calif. and...
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
01 août 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
18 juil. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, July 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“MainzBiomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Secures up to $50M in New Funding
29 juin 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
28 juin 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early...
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
20 juin 2023 03h01 HE
|
Mainz BioMed NV
ColoAlert® will be offered to an addressable market of 6 million patients through 15 laboratories. BERKELEY, Calif. and MAINZ, Germany, June 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV...
Mainz Biomed Expands Commercial Footprint into Poland
31 mai 2023 03h01 HE
|
Mainz BioMed NV
Total addressable market in Poland is estimated at 21 million patients BERKELEY, Calif. and MAINZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the...
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
24 mai 2023 03h01 HE
|
Mainz BioMed NV
Employees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient BERKELEY, Calif. and MAINZ, Germany, May 24, 2023 (GLOBE NEWSWIRE) --...
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
16 mai 2023 03h01 HE
|
Mainz BioMed NV
ColoAlert® Revenue Increases 152% Year Over Year BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a...